Neural Regeneration Research ›› 2026, Vol. 21 ›› Issue (9): 4239-4240.doi: 10.4103/NRR.NRR-D-25-01189

Previous Articles     Next Articles

Targeting the NLRP3–NEK7 axis with rebamipide: Drug repurposing in Parkinson’s disease

Hye-Sun Lim, Gunhyuk Park*   

  1. Herbal Medicine Resources Research Center, Korea Institute of Oriental Medicine, Naju-si, Jeollanam-do, Republic of Korea
  • Online:2026-09-15 Published:2026-05-11
  • Contact: Gunhyuk Park, PhD, gpark@kiom.re.kr or parkgunhyuk@gmail.com.
  • Supported by:
    This work was supported by a grant on the development of sustainable application for standard herbal resources (KSN1823320), by a grant on the development of innovative technologies for the future value of herbal medicine resources (KSN2511030), and development of an upcycling platform technology for food waste utilization (KSN2511040) from the Korea Institute of Oriental Medicine, and by a grant on the Pharmacokinetic interaction and mechanistic investigation using isobologram and multi-omics analysis of traditional Korean medicine and western medicine concomitant therapy for establishing therapeutic basis in the treatment of Alzheimer’s disease (RS-2024–00352796) from the National Research Foundation of Korea, Republic of Korea (to GP).

PDF

2

Abstract: Introduction — from traditional wisdom to modern challenges: Drug repurposing has become a strategic pillar in pharmaceutical development, addressing the rising challenges of novel drug discovery (Saranraj and Kiran, 2025). The conventional pipeline is often arduous > $2 billion per approval, with < 10% clinical success. The burden is even heavier in programs in the central nervous system (CNS) due to the blood–brain barrier, disease heterogeneity, and limited biomarkers (Saranraj and Kiran, 2025). These inefficiencies create a bottleneck for neurodegenerative diseases, underscoring the need for faster, lower-risk strategies such as drug repurposing to deliver therapies more quickly.